Eagle Bay Advisors LLC Sells 579 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Eagle Bay Advisors LLC lessened its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) by 45.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 708 shares of the company’s stock after selling 579 shares during the period. Eagle Bay Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $35,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PBH. Advisor Group Holdings Inc. boosted its stake in shares of Prestige Consumer Healthcare by 10.9% during the first quarter. Advisor Group Holdings Inc. now owns 3,694 shares of the company’s stock valued at $196,000 after purchasing an additional 363 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Prestige Consumer Healthcare by 10.8% during the first quarter. JPMorgan Chase & Co. now owns 210,242 shares of the company’s stock valued at $11,130,000 after purchasing an additional 20,496 shares in the last quarter. Raymond James & Associates boosted its stake in shares of Prestige Consumer Healthcare by 84.8% during the first quarter. Raymond James & Associates now owns 9,326 shares of the company’s stock valued at $494,000 after purchasing an additional 4,279 shares in the last quarter. US Bancorp DE boosted its stake in shares of Prestige Consumer Healthcare by 67.7% during the first quarter. US Bancorp DE now owns 10,237 shares of the company’s stock valued at $541,000 after purchasing an additional 4,132 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in shares of Prestige Consumer Healthcare by 6.0% during the first quarter. HighTower Advisors LLC now owns 5,791 shares of the company’s stock valued at $307,000 after purchasing an additional 330 shares in the last quarter. Institutional investors own 99.98% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $61.78 on Friday. The firm has a market cap of $3.07 billion, a PE ratio of 14.82, a price-to-earnings-growth ratio of 1.76 and a beta of 0.56. Prestige Consumer Healthcare Inc. has a 52-week low of $48.51 and a 52-week high of $67.45. The business’s 50 day moving average price is $62.53 and its two-hundred day moving average price is $58.26. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.56 and a current ratio of 2.55.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last released its earnings results on Thursday, February 2nd. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $275.50 million for the quarter, compared to the consensus estimate of $273.84 million. Prestige Consumer Healthcare had a net margin of 18.97% and a return on equity of 12.65%. Prestige Consumer Healthcare’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.99 EPS. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PBH shares. Oppenheimer cut their price target on Prestige Consumer Healthcare from $72.00 to $71.00 and set an “outperform” rating on the stock in a research note on Friday, February 17th. Canaccord Genuity Group started coverage on Prestige Consumer Healthcare in a research note on Thursday, November 17th. They issued a “buy” rating and a $71.00 price objective on the stock. Finally, StockNews.com started coverage on Prestige Consumer Healthcare in a research note on Thursday. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and an average price target of $70.75.

Prestige Consumer Healthcare Company Profile

(Get Rating)

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.